This Life Science event will have Dr. Jasper Bos, Senior Vice President and Managing Director of the M Ventures Healthcare fund, presenting an overview of the fund, its investment strategy and primary areas of interest as well as some interesting case studies. A special example of...

BaseLaunch supports carefully selected ventures in two phases. After a very intense pressure test period, four projects were selected for Phase II of our second year. They now have the opportunity to further advance their breakthrough healthcare innovation and secure further investment. With support from its...

 The physician and pharmacologist Nicole Onetto is a member of the Board of Directors at the Basilea Pharmaceutica AG. In the Interview that was featured in Basilea’s annual report she talks about current challenges in oncology. Great strides are being made in the long-term treatment of...

The serial entrepreneur Neil Goldsmith is drawn to new ventures. Annett Altvater from BaselArea.swiss talked to him about how to detect startup-suitable talent and his current involvement with BaseLaunch. You founded and led a number of companies over the last 30 years. How did you know...

The Swiss biotech industry continued to grow in 2017. Reaching record figures in sales and capital investments in companies, according to a new report. New biotech facilities are expected to further increase export volumes. The 297 companies in the Swiss biotech industry increased their sales by...

Biotech is a lot like venture capital. Vast amounts of research, testing and marketing go into a wide range of therapies. But in the end, it’s just a tiny fraction that deliver most returns. That similarity may be why most of the biggest biotech and pharmaceutical...